{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:27:09Z","timestamp":1792553229020,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":904,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023181","name":"Agencja Bada\u0144 Medycznych","doi-asserted-by":"publisher","award":["2021\/ABM\/03\/00008"],"award-info":[{"award-number":["2021\/ABM\/03\/00008"]}],"id":[{"id":"10.13039\/501100023181","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023181","name":"Agencja Bada\u0144 Medycznych","doi-asserted-by":"publisher","award":["2021\/ABM\/03\/00008"],"award-info":[{"award-number":["2021\/ABM\/03\/00008"]}],"id":[{"id":"10.13039\/501100023181","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>In recent years, survival in patients with breast cancer has increased. Despite the improvement in outcomes of those patients, the risk of treatment-related cardiotoxicity remains high, and its presence has been associated with a higher risk of treatment termination and thus lower therapeutic efficacy. Prior trials demonstrated that a preventive initiation of heart failure drugs, including the renin\u2013angiotensin\u2013aldosterone inhibitors, might reduce the risk of treatment-related cardiotoxicity. However, to date, no study investigated the efficacy of sacubitril\/valsartan, a novel antineurohormonal drug shown to be superior to the previous therapies, in the prevention of cardiotoxicity in patients with early-stage breast cancer, which is the aim of the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>MAINSTREAM is a randomized, placebo-controlled, double-blind, multicentre, clinical trial. After the run-in period, a total of 480 patients with early breast cancer undergoing treatment with anthracyclines and\/or anti-human epidermal growth factor receptor 2 drugs will be randomized to the highest tolerated dose of sacubitril\/valsartan, being preferably 97\/103 mg twice daily or placebo in 1:1 ratio. The patients will be monitored, including routine transthoracic echocardiography (TTE) and laboratory biomarker monitoring, for 24 months. The primary endpoint of the trial will be the occurrence of a decrease in left ventricular ejection fraction by \u22655% in TTE within 24 months. The key secondary endpoints will be the composite endpoint of death from any cause or hospitalization for heart failure, as well as other imaging, laboratory, and clinical outcomes, including the occurrence of the cancer therapy-related cardiac dysfunction resulting in the necessity to initiate treatment. The first patients are expected to be recruited in the coming months, and the estimated completion of the study and publication of the results are expected in December 2027, pending recruitment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The MAINSTREAM trial will determine the efficacy and safety of treatment with sacubitril\/valsartan as a prevention of cardiotoxicity in patients with early breast cancer (ClinicalTrials.gov number: NCT05465031).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14466","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T07:33:46Z","timestamp":1689320026000},"page":"3174-3183","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Sacubitril\/Valsartan for Cardioprotection in Breast Cancer (MAINSTREAM): Design and Rationale of the Randomized Trial"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-5485","authenticated-orcid":false,"given":"Mateusz","family":"Tajstra","sequence":"first","affiliation":[{"name":"3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia , Katowice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2506-2430","authenticated-orcid":false,"given":"Maciej","family":"Dyrbu\u015b","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia , Katowice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8818-6126","authenticated-orcid":false,"given":"Tomasz","family":"Rutkowski","sequence":"additional","affiliation":[{"name":"Department of Radiation and Clinical Oncology, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Gliwice Branch , Gliwice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0554-6171","authenticated-orcid":false,"given":"Krzysztof","family":"Sk\u0142adowski","sequence":"additional","affiliation":[{"name":"Department of Radiation and Clinical Oncology, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Gliwice Branch , Gliwice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3536-8035","authenticated-orcid":false,"given":"Barbara","family":"Sosnowska-Pasiarska","sequence":"additional","affiliation":[{"name":"Department of Oncocardiology, Holy Cross Cancer Centre , Kielce ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6902-3807","authenticated-orcid":false,"given":"Stanis\u0142aw","family":"G\u00f3\u017ad\u017a","sequence":"additional","affiliation":[{"name":"Holy Cross Cancer Centre , Kielce ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7979-7523","authenticated-orcid":false,"given":"Barbara","family":"Radecka","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institute of Medical Sciences, University of Opole , Opole ,","place":["Poland"]},{"name":"Department of Clinical Oncology, Tadeusz Koszarowski Cancer Centre in Opole , Opole ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Staszewski","sequence":"additional","affiliation":[{"name":"Tadeusz Koszarowski Cancer Centre in Opole , Opole ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Majsnerowska","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia , Katowice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5564-6920","authenticated-orcid":false,"given":"Krzysztof","family":"Myrda","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia , Katowice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8709-4721","authenticated-orcid":false,"given":"Alicja","family":"Nowowiejska-Wiewi\u00f3ra","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia , Katowice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Skoczylas","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia , Katowice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Rymkiewicz","sequence":"additional","affiliation":[{"name":"Silesian Centre for Heart Diseases , Zabrze ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Niklewski","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Medical University of Silesia, Silesian Centre for Heart Diseases , Zabrze ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0462-0154","authenticated-orcid":false,"given":"Jolanta","family":"Nowak","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia , Katowice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-3219","authenticated-orcid":false,"given":"Piotr","family":"Przyby\u0142owski","sequence":"additional","affiliation":[{"name":"Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Medical University of Silesia, Silesian Centre for Heart Diseases , Zabrze ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6775-1392","authenticated-orcid":false,"given":"Mariusz","family":"G\u0105sior","sequence":"additional","affiliation":[{"name":"3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia , Katowice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2642-9724","authenticated-orcid":false,"given":"Micha\u0142","family":"Jarz\u0105b","sequence":"additional","affiliation":[{"name":"Breast Cancer Unit, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Gliwice Branch , Gliwice ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"2026012113213719000_ehf214466-bib-0001","volume-title":"Breast cancer statistics [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0002","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0003","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0004","first-page":"13","article-title":"Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers","volume":"1","author":"Mohan","year":"2018","journal-title":"Antib Ther [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tcm.2019.01.006","article-title":"Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity","volume":"30","author":"Padegimas","year":"2020","journal-title":"Trends Cardiovasc Med [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0006","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/2042098614529603","article-title":"Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors","volume":"5","author":"Onitilo","year":"2014","journal-title":"Ther Adv Drug Saf [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0007","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/annonc\/mdf132","article-title":"Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients","volume":"13","author":"Jensen","year":"2002","journal-title":"Ann Oncol Off J Eur Soc Med Oncol [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0008","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"143","author":"Heck","year":"2021","journal-title":"Circulation [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0009","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0010","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"JACC Adv"},{"key":"2026012113213719000_ehf214466-bib-0011","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0012","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0013","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40959-020-00078-4","article-title":"Use of sacubitril\/valsartan in patients with cardio toxicity and heart failure due to chemotherapy","volume":"6","author":"Gregorietti","year":"2020","journal-title":"Cardio-oncology (London, England)"},{"key":"2026012113213719000_ehf214466-bib-0014","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ehf2.12627","article-title":"Effectiveness of sacubitril\u2013valsartan in cancer patients with heart failure","volume":"7","author":"Mart\u00edn-Garcia","year":"2020","journal-title":"ESC Hear Fail [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0015","first-page":"207","article-title":"Breast cancer","volume":"16","author":"Jassem","year":"2020","journal-title":"Oncol Clin Pract"},{"key":"2026012113213719000_ehf214466-bib-0016","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.306.6890.1440","article-title":"The SF36 health survey questionnaire: an outcome measure suitable for routine use within the NHS?","volume":"306","author":"Garratt","year":"1993","journal-title":"BMJ [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0017","article-title":"Physician adherence and patient-reported outcomes in heart failure with reduced ejection fraction in the era of angiotensin receptor-neprilysin inhibitor therapy","volume":"12","author":"Kim","year":"2022","journal-title":"Sci Rep [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0018","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1373\/clinchem.2008.106500","article-title":"Clinical performance of two highly sensitive cardiac troponin I assays","volume":"55","author":"Venge","year":"2009","journal-title":"Clin Chem [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0019","article-title":"Year in cardiovascular medicine: cardio-oncology 2020-21","author":"Herrmann","year":"2022","journal-title":"Eur Heart J [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0020","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jaccao.2019.11.007","article-title":"Proceedings from the Global Cardio-Oncology Summit: the top 10 priorities to actualize for cardiooncology","volume":"1","author":"Lenihan","year":"2019","journal-title":"JACC CardioOncology [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0021","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0022","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0023","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.hfc.2018.08.007","article-title":"Breast cancer and heart failure","volume":"15","author":"Almuwaqqat","year":"2019","journal-title":"Heart Fail Clin [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0024","article-title":"Cardiac toxicity from adjuvant targeting treatment for breast cancer post-surgery","volume":"12","author":"Fu","year":"2022","journal-title":"Front Oncol [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00280-021-04254-w","article-title":"Cardiovascular toxicity of breast cancer treatment: an update","volume":"88","author":"Papageorgiou","year":"2021","journal-title":"Cancer Chemother Pharmacol [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0026","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012113213719000_ehf214466-bib-0027","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"2026012113213719000_ehf214466-bib-0028","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012113213719000_ehf214466-bib-0029","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1291\/hypres.25.597","article-title":"Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy","volume":"25","author":"Toko","year":"2002","journal-title":"Hypertens Res [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0030","article-title":"The efficacy and safety of sacubitril\/valsartan in heart failure patients: a review","volume":"27","author":"Zhang","journal-title":"J Cardiovasc Pharmacol Ther [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0031","first-page":"12114","article-title":"The efficacy and safety of sacubitril\/valsartan in the treatment of chronic heart failure: a meta-analysis","volume":"13","author":"Zheng","year":"2021","journal-title":"Am J Transl Res [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0032","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijcard.2021.11.059","article-title":"Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: the HFA\/ICOS risk tool in real-world practice","volume":"15","author":"Tini","year":"2022","journal-title":"Int J Cardiol [Internet]"},{"key":"2026012113213719000_ehf214466-bib-0033","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-021-06192-w","article-title":"Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer","volume":"188","author":"Battisti","year":"2021","journal-title":"Breast Cancer Res Treat [Internet]"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/5\/3174\/66228019\/eschf_10_5_3174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/5\/3174\/66228019\/eschf_10_5_3174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:26:31Z","timestamp":1769019991000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/5\/3174\/8284419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,7,14]]},"published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14466","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,7,14]]},"assertion":[{"value":"2023-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}